	US 11,780,924 B2
	HLA binding vaccine moieties and uses thereof
Gunnveig Grodeland, Oslo (NO); Bjarne Bogen, Oslo (NO); and Agnete B. Fredriksen, Oslo (NO)
Assigned to UNIVERSITY OF OSLO, Oslo (NO); and NYKODE THERAPEUTICS ASA, Oslo (NO)
Appl. No. 16/312,337
Filed by UNIVERSITY OF OSLO, Oslo (NO); and NYKODE THERAPEUTICS AS, Oslo (NO)
PCT Filed Jun. 21, 2017, PCT No. PCT/IB2017/000946 § 371(c)(1), (2) Date Dec. 21, 2018, PCT Pub. No. WO2017/221072, PCT Pub. Date Dec. 28, 2017.
Claims priority of provisional application 62/352,815, filed on Jun. 21, 2016.
Prior Publication US 2021/0403572 A1, Dec. 30, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01); C07K 16/34 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2833 (2013.01) [A61K 39/00 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); C07K 16/34 (2013.01); C07K 16/46 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01)]

12 Claims

1. A nucleic acid comprising a sequence encoding an antibody, a scFv or a Fab fragment comprising light chain complementarity determining region (LCDR) 1 of SEQ ID NO:4; LCDR 2 of SEQ ID NO:5; and LCDR 3 of SEQ ID NO:6; and heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO:7; HCDR 2 of SEQ ID NO:8 and; HDCR 3 of SEQ ID NO:9.